✦ LIBER ✦

Anal Mucosal Melanoma with KIT -Activating Mutation and Response to Imatinib Therapy – Case Report and Review of the Literature

✍ Scribed by Satzger, Imke; Küttler, Uta; Völker, Bernward; Schenck, Florian; Kapp, Alexander; Gutzmer, Ralf

Book ID: 121810034
Publisher: S. Karger AG
Year: 2010
Tongue: English
Weight: 728 KB
Volume: 220
Category: Article
ISSN: 1018-8665
DOI: 10.1159/000265558

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

C-kit-positive acute myelogenous leukemi

C-kit-positive acute myelogenous leukemia effectively treated with imatinib: A case report and review of the literature

✍ Kunimoto Ichikawa; Nanae Aritaka; Yasunobu Sekiguchi; Kei-ji Sugimoto; Hidenori 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

Metastatic Rhabdoid Meningioma with BRAF

Metastatic Rhabdoid Meningioma with BRAF V600E Mutation and Good Response to Personalized Therapy: Case Report and Review of the Literature

✍ Mordechai, Oz; Postovsky, Sergey; Vlodavsky, Eugene; Eran, Ayelet; Constantini, 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 445 KB

Oral mucosal pigmentation secondary to m

Oral mucosal pigmentation secondary to minocycline therapy: report of two cases and a review of the literature

✍ Nathaniel S. Treister; Daniel Magalnick; Sook-Bin Woo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 536 KB

Response of imatinib-resistant extra-abd

Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors

✍ Keith M. Skubitz; J. Carlos Manivel; Denis R. Clohisy; Jerry W. Frolich 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 386 KB

Post-thrombocythemic myeloid metaplasia

Post-thrombocythemic myeloid metaplasia with pleural involvement and the duration of response to external beam radiation therapy: a case report and literature review

✍ Churilla, Thomas M.; Saidman, Bruce H.; Mullen, Matthew G.; Peters, Christopher 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 191 KB

Is it possible to discontinue imatinib m

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

✍ Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o